Literature DB >> 16874206

Suicide bombing injuries: the Jerusalem experience of exceptional tissue damage posing a new challenge for the reconstructive surgeon.

Dean D Ad-El1, Arie Eldad, Yoav Mintz, Yacov Berlatzky, Amir Elami, Avraham I Rivkind, Gideon Almogy, Tomer Tzur.   

Abstract

BACKGROUND: Suicide bomb injuries vary in form and magnitude. From the onset of the second Palestinian "intifada" in October of 2000 until January of 2004, 577 victims of suicide bombings were admitted to the Hadassah-Hebrew University Medical Center. A single bomber carrying a handbag or belt containing multiple metal objects and explosives carried out most of the attacks. As a result, many of the victims suffered massive tissue destruction in addition to conventional blast injuries.
METHODS: This article describes the management of this trauma-related "syndrome" of combined primary and high-magnitude secondary blast injury.
RESULTS: The management of the extensive soft-tissue damage is described and two representative cases presented.
CONCLUSION: Suicide bombing-related injuries in their present form are a true challenge for the reconstructive surgeon.

Entities:  

Mesh:

Year:  2006        PMID: 16874206     DOI: 10.1097/01.prs.0000227736.91811.c7

Source DB:  PubMed          Journal:  Plast Reconstr Surg        ISSN: 0032-1052            Impact factor:   4.730


  3 in total

Review 1.  Characterization of the response to primary blast injury.

Authors:  E Kirkman; S Watts
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2011-01-27       Impact factor: 6.237

2.  Neutrality, conflict, and structural determinants of health in a Jerusalem emergency department.

Authors:  Zvika Orr; Levi Jackson; Evan Avraham Alpert; Mark D Fleming
Journal:  Int J Equity Health       Date:  2022-06-24

3.  Fatal and non-fatal injuries due to intentional explosions in Nepal, 2008-2011: analysis of surveillance data.

Authors:  Oleg O Bilukha; Kristin Becknell; Hugues Laurenge; Luhar Danee; Krishna P Subedi
Journal:  Confl Health       Date:  2013-03-20       Impact factor: 2.723

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.